LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Strona główna・Stock List・Kura Oncology Inc

Kura Oncology Inc

Closed

SectorHealthcare

11.16 8.56

Buy Sell

Overview

Share price change

24h

Current

Min

10.19

Max

11.45

Key metrics
By Trading Economics
Income	7.7M -73M
Sales	929K 18M
Profit margin	-401.495
Employees	260
EBITDA	7.4M -78M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+213.95% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-31M 813M
Previous open	2.6
Previous close	11.16

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.575 / 6.6 Support & Resistance

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 maj 2026, 22:48 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 maj 2026, 16:49 UTC

Earnings

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 maj 2026, 16:26 UTC

Major Market Movers

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 maj 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 maj 2026, 23:37 UTC

Earnings

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 maj 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 maj 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 maj 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Conduent to Sell Public Transit Business to Modaxo for $164M

21 maj 2026, 21:53 UTC

Earnings

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 maj 2026, 21:02 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 maj 2026, 20:55 UTC

Earnings

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 maj 2026, 20:30 UTC

Hot Stocks

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 maj 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 maj 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Adj EPS 3c >BULL

21 maj 2026, 20:20 UTC

Earnings

Webull 1Q Rev $159.9M >BULL

21 maj 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 maj 2026, 20:18 UTC

Earnings

Webull 1Q Loss/Shr 4c

21 maj 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 maj 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 maj 2026, 18:58 UTC

Earnings

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 maj 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 maj 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 maj 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 maj 2026, 17:01 UTC

Earnings

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 maj 2026, 16:20 UTC

Market Talk

Earnings

Stellantis Targets Distant but Constructive -- Market Talk

21 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

213.95% upside

12 Months Forecast

Average 28.13 USD 213.95%

High 40 USD

Low 15 USD

Based on 10 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.